Npa7, a First in Class Dual Receptor Activator With Cardio-Renoprotective Properties in Vivo

Meems, Laura M.G.; Andersen, Ingrid A.; Huntley, Brenda K.; Harty, Gail J.; Yang, Chen Chang; Heublein, Denise M.; Iyer, Seethalakshmi; Pan, Shanlin; McCormick, D. J.; Ichiki, Tomoko; Burnett, John C.

doi:10.1016/s0735-1097(17)35943-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, independent MasR activation contributes to antiapoptotic, anti-inflammatory, vasodilatory, and antithrombotic effects through its secondary messenger cAMP (Tables 1 and 2 ). Subcutaneous administration of NPA7 mediated cardiac unloading and diuretic, natriuretic and RAAS-suppressing actions in healthy canines [ 70 ]. NPA7 proved superior in hemodynamic effects, natriuresis, diuresis and cardiorenoprotective effects in heart failure models [ 71 ].…”

Section: Novel Therapeutic Approaches Targeting Raas In Hypertension mentioning

confidence: 99%

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

et al. 2021

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) is responsible for maintaining blood pressure and vascular tone. Modulation of the RAAS, therefore, interferes with essential cellular processes and leads to high blood pressure, oxidative stress, inflammation, fibrosis, and hypertrophy. Consequently, these conditions cause fatal cardiovascular and renal complications. Thus, the primary purpose of hypertension treatment is to diminish or inhibit overactivated RAAS. Currently available RAAS inhibitors have proven effective in reducing blood pressure; however, beyond hypertension, they have failed to treat end-target organ injury. In addition, RAAS inhibitors have some intolerable adverse effects, such as hyperkalemia and hypotension. These gaps in the available treatment for hypertension require further investigation of the development of safe and effective therapies. Current research is focused on the combination of existing and novel treatments that neutralize the angiotensin II type I (AT1) receptor-mediated action of the angiotensin II peptide. Preclinical studies of peptide- and nonpeptide-based therapeutic agents demonstrate their conspicuous impact on the treatment of cardiovascular diseases in animal models. In this review, we will discuss novel therapeutic agents being developed as RAAS inhibitors that show prominent effects in both preclinical and clinical studies. In addition, we will also highlight the need for improvement in the efficacy of existing drugs in the absence of new prominent antihypertensive drugs.

show abstract

Section: Novel Therapeutic Approaches Targeting Raas In Hypertension mentioning

confidence: 99%

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

et al. 2021

View full text Add to dashboard Cite

show abstract

Npa7, a First in Class Dual Receptor Activator With Cardio-Renoprotective Properties in Vivo

Cited by 1 publication

References 0 publications

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

Novel therapeutics for the treatment of hypertension and its associated complications: peptide- and nonpeptide-based strategies

Contact Info

Product

Resources

About